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Dear Editor 
We read with interest the recent DOOR/RADAR proposal to transform non-inferiority into 
superiority trials1. We agree with the authors that non-inferiority trials are complex to conduct, 
often have large, impractical sample sizes and are prone to biases and manipulation compared to 
superiority trials. 
Antimicrobial resistance is perhaps the greatest challenge facing healthcare today2. We therefore 
welcome their laudable attempt to consider radical and pragmatic alternatives to non-inferiority 
trials. We are concerned, however, that DOOR/RADAR suffers from several flaws and may therefore 
not represent a viable alternative to non-inferiority trials. 
Firstly, a clinical interpretation for the proposed treatment effect of ‘the probability of a better 
DOOR for a randomly selected participant from the new vs. the old strategy’ is far from clear. The 
authors arbitrarily propose 60% for the alternative hypothesis for sample size calculations. 
Introducing a completely new effect measure may increase rather than reduce complexity, and 
could potentially be misinterpreted. 
Secondly, despite the superiority framework, intention-to-treat analyses do not retain their standard 
interpretation since, providing patients experience good outcomes, the intervention will always be 
ranked higher than the control regardless of treatment actually received.  
Thirdly, combining clinical outcome and treatment duration into a single variable, obscures 
important differences in the clinical outcome. DOOR/RADAR will show superiority even if there is an 
imbalance between arms in an important clinical outcome (say death) provided it occurs in a 
relatively small proportion of patients and the more favourable outcomes are reasonably well 
balanced between arms.  
To illustrate, we applied DOOR/RADAR to the recently completed non-inferiority trials RIFAQUIN3 
and REMoxTB4, where three different 4-month regimens were shown not to be non-inferior to the 6-
month control regimen using a pre-specified 6% non-inferiority margin. There was strong evidence 
(p<0.0001) that each 4-month regimen had a higher DOOR than the standard 6-month regimen 
(Table) using either a 4-category or 7-category clinical outcome, with treatment effects of 0.66-0.68 
and 0.62-0.64 respectively. This is not unsurprising given that >50% of patients had the most 
successful outcome on each arm (favourable clinical outcome with no grade 3/4 adverse events) and 
therefore the DOOR is driven by the shorter treatment duration in the 4-month arms by design 
rather than the poorer outcomes on the 4-month regimens. It is hard to see what this adds to the 
standard non-inferiority analysis of the trials given that there has been unanimous consensus that 
none of these regimens are viable alternatives to the standard 6-month regimen.  
Power in DOOR/RADAR is maximised with a clinical outcome with fewer categories, or where most 
patients fall into a small number of categories, as illustrated by the higher treatment effects and z-
scores with the 4-category than the 7-category outcome in our example. Thus DOOR/RADAR can be 
manipulated by careful choice of the clinical outcome to increase the chance of superiority.  
The SCOUT-CAP trial has been designed based on DOOR/RADAR; our results suggest that 
considerable further evaluation of this approach is urgently needed to avoid an inconclusive result 
with no impact on clinical practice.  
  
 
 
 
Table. Application of the DOOR/RADAR approach to the shorter duration 4-month regimens from 
the REMoxTB and RIFAQUIN trials. The 4-category and 7-category clinical outcomes are based on a 
composite of the primary efficacy and safety endpoints from the trials. Patients excluded from the 
primary analyses based on pre-randomisation data were also excluded in this analysis (modified 
intention-to-treat). 
 
4-category clinical outcome: 
1. Favourable with no grade 3 or 4 
adverse events; 
2. Favourable with at least one 
grade 3 or 4 adverse event; 
3. Not assessable; 
4. Unfavourable. 
7-category clinical outcome: 
1. Favourable (culture negative at end 
of follow-up) with no grade 3 or 4 
adverse events; 
2. Favourable (REMoxTB: no negative 
culture at end of follow-up, RIFAQUIN: 
follow-up curtailed <18m by protocol 
amendment) with no grade 3 or 4 
adverse events; 
3. Favourable with at least one grade 3 
or 4 adverse event; 
4. Not assessable; 
5. Unfavourable (not relapse or 
treatment failure); 
6. Unfavourable (relapse or treatment 
failure without culture confirmation); 
7. Unfavourable (culture confirmed 
relapse or treatment failure). 
Treatment arm 
(compared to 
standard 6-
month regimen) 
Probability of a 
better DOOR for 
a randomly 
selected 
participant from 
the new 
strategy (95% 
CI)* 
Test that new 
strategy has a 
higher DOOR** 
Probability of a 
better DOOR for 
a randomly 
selected 
participant from 
the new strategy 
(95% CI)* 
Test that new 
strategy has a higher 
DOOR** 
REMoxTB: 
Moxifloxacin and 
ethambutol 
regimen 
0.68 (0.64, 0.72) 
p < 0.0001 (z = 
10.7) 
0.62 (0.59, 0.65) p < 0.0001 (z = 7.4) 
REMoxTB: 
Moxifloxacin and 
isoniazid regimen 
0.68 (0.65, 0.72) 
p < 0.0001 (z = 
10.8) 
0.64 (0.60, 0.67) p < 0.0001 (z = 8.2) 
RIFAQUIN: 
Moxifloxacin and 
rifapentine 
0.66 (0.60, 0.71) 
p < 0.0001 (z = 
6.0) 
0.62 (0.56, 0.67) p < 0.0001 (z = 4.4) 
* 95% bootstrap percentile confidence intervals. ** Wilcoxon rank-sum test.  
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